State of Alaska Department of Revenue Sells 7,481 Shares of Protagonist Therapeutics, Inc. $PTGX

State of Alaska Department of Revenue lessened its holdings in shares of Protagonist Therapeutics, Inc. (NASDAQ:PTGX) by 20.3% in the third quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 29,425 shares of the company’s stock after selling 7,481 shares during the quarter. State of Alaska Department of Revenue’s holdings in Protagonist Therapeutics were worth $1,954,000 as of its most recent SEC filing.

Several other institutional investors have also recently bought and sold shares of PTGX. American Century Companies Inc. raised its position in Protagonist Therapeutics by 18.7% in the 2nd quarter. American Century Companies Inc. now owns 813,995 shares of the company’s stock valued at $44,990,000 after buying an additional 128,171 shares during the last quarter. Segall Bryant & Hamill LLC purchased a new position in Protagonist Therapeutics during the 2nd quarter worth $6,641,000. Voya Investment Management LLC grew its stake in shares of Protagonist Therapeutics by 8.9% in the 3rd quarter. Voya Investment Management LLC now owns 305,419 shares of the company’s stock worth $20,289,000 after acquiring an additional 25,065 shares in the last quarter. Nan Fung Trinity HK Ltd. purchased a new stake in shares of Protagonist Therapeutics in the second quarter valued at about $7,464,000. Finally, Creative Planning lifted its position in shares of Protagonist Therapeutics by 74.3% during the second quarter. Creative Planning now owns 30,204 shares of the company’s stock valued at $1,669,000 after purchasing an additional 12,871 shares in the last quarter. Institutional investors and hedge funds own 98.63% of the company’s stock.

Analysts Set New Price Targets

A number of equities research analysts have issued reports on PTGX shares. Wedbush upped their price objective on shares of Protagonist Therapeutics from $70.00 to $86.00 and gave the stock an “outperform” rating in a research report on Tuesday, October 28th. BMO Capital Markets restated an “outperform” rating on shares of Protagonist Therapeutics in a research note on Monday, October 13th. JPMorgan Chase & Co. increased their price target on Protagonist Therapeutics from $68.00 to $81.00 and gave the company an “overweight” rating in a research report on Friday, November 7th. Weiss Ratings upgraded Protagonist Therapeutics from a “sell (d+)” rating to a “hold (c-)” rating in a report on Wednesday, December 24th. Finally, Citizens Jmp raised their target price on Protagonist Therapeutics from $69.00 to $102.00 and gave the company a “market outperform” rating in a research report on Friday, November 7th. One equities research analyst has rated the stock with a Strong Buy rating, eleven have given a Buy rating and two have issued a Hold rating to the stock. Based on data from MarketBeat.com, Protagonist Therapeutics has an average rating of “Moderate Buy” and a consensus target price of $86.77.

Protagonist Therapeutics Trading Up 4.8%

NASDAQ:PTGX opened at $85.23 on Thursday. Protagonist Therapeutics, Inc. has a 12 month low of $33.70 and a 12 month high of $96.54. The firm’s 50 day moving average is $86.50 and its 200 day moving average is $70.28. The stock has a market capitalization of $5.33 billion, a PE ratio of 137.47 and a beta of 2.26.

Protagonist Therapeutics (NASDAQ:PTGX) last released its earnings results on Thursday, November 6th. The company reported ($0.62) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.59) by ($0.03). The firm had revenue of $4.71 million during the quarter, compared to analysts’ expectations of $5.41 million. Protagonist Therapeutics had a return on equity of 6.86% and a net margin of 21.94%. Research analysts predict that Protagonist Therapeutics, Inc. will post 2.43 earnings per share for the current year.

Protagonist Therapeutics Profile

Protagonist Therapeutics, Inc (NASDAQ: PTGX) is a clinical-stage biopharmaceutical company focused on the development of novel, orally administered peptide-based therapies for immune-mediated and other serious diseases. The company leverages its proprietary Peptide 2.0 platform to design peptides that target G protein–coupled receptors and cytokine receptors, with the goal of combining the potency of biologics with the convenience of oral administration. Protagonist’s approach aims to address unmet medical needs in areas where injectable therapies have been the standard of care.

Among its lead programs is PTG-100, an oral α4β7 integrin antagonist intended to block leukocyte migration to the gut in ulcerative colitis and Crohn’s disease.